Abstract
Recent research has made striking advances, adding to our understanding of the aethiopathogenesis of several forms of secondary osteoporosis, including those associated with rheumatic diseases and glucocorticoid treatment. Furthermore, in the last 3 years new drugs have been shown to prevent glucocorticoid-induced bone loss. Guidelines that are suitable for clinical practice have been published. Knowledge of those new opportunities and strategies, which are briefly reviewed in this article, will reduce the risk of osteoporotic fractures in rheumatic and non-rheumatic patients.
| Original language | English (US) |
|---|---|
| Journal | Clinical and Experimental Rheumatology |
| Volume | 18 |
| Issue number | 5 SUPPL. 21 |
| State | Published - 2000 |
| Externally published | Yes |
Fingerprint
Keywords
- Glucocorticoids
- Osteoporosis
- Prevention
- Rheumatic diseases
- Treatment
ASJC Scopus subject areas
- Immunology
- Rheumatology
Cite this
Rheumatic diseases, glucocorticoid treatment and bone mass : Recent developments. / Mazzantini, M.; Lane, Nancy E.
In: Clinical and Experimental Rheumatology, Vol. 18, No. 5 SUPPL. 21, 2000.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Rheumatic diseases, glucocorticoid treatment and bone mass
T2 - Recent developments
AU - Mazzantini, M.
AU - Lane, Nancy E
PY - 2000
Y1 - 2000
N2 - Recent research has made striking advances, adding to our understanding of the aethiopathogenesis of several forms of secondary osteoporosis, including those associated with rheumatic diseases and glucocorticoid treatment. Furthermore, in the last 3 years new drugs have been shown to prevent glucocorticoid-induced bone loss. Guidelines that are suitable for clinical practice have been published. Knowledge of those new opportunities and strategies, which are briefly reviewed in this article, will reduce the risk of osteoporotic fractures in rheumatic and non-rheumatic patients.
AB - Recent research has made striking advances, adding to our understanding of the aethiopathogenesis of several forms of secondary osteoporosis, including those associated with rheumatic diseases and glucocorticoid treatment. Furthermore, in the last 3 years new drugs have been shown to prevent glucocorticoid-induced bone loss. Guidelines that are suitable for clinical practice have been published. Knowledge of those new opportunities and strategies, which are briefly reviewed in this article, will reduce the risk of osteoporotic fractures in rheumatic and non-rheumatic patients.
KW - Glucocorticoids
KW - Osteoporosis
KW - Prevention
KW - Rheumatic diseases
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=0033769119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033769119&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0033769119
VL - 18
JO - Clinical and Experimental Rheumatology
JF - Clinical and Experimental Rheumatology
SN - 0392-856X
IS - 5 SUPPL. 21
ER -